Uzin Utz SE

Latest Results (27.12.2025):

Uzin Utz SE — reporting on the financial year 2024 (includes Q4 2024 as part of the full‑year results). For FY 2024 the Group reported total external sales of EUR 476,034k (FY 2023: EUR 479,337k) and a materially improved operating result: Group EBIT rose to EUR 42,815k (FY 2023: EUR 34,505k). Group net assets increased to EUR 280,289k (2023: EUR 257,290k), while investments (capex) were EUR 20,895k (2023: EUR 27,388k).

Top‑line

Group external sales slightly declined year‑on‑year to EUR 476,034k from EUR 479,337k (≈ ‑0.7%). Geographically, Germany remained the largest market (EUR 168,391k), the Netherlands EUR 86,865k and the Americas EUR 75,630k. No single customer accounted for more than 10% of Group revenue.

Profitability (EBIT)

Operating profit (EBIT) improved significantly to EUR 42,815k (2023: EUR 34,505k), a rise of about EUR 8.3m or ~24%. This improvement reflects stronger segment results and consolidations; depreciation increased to EUR 21,460k (2023: EUR 18,732k).

Key segment performance

Germany (largest segment) generated external sales of EUR 155,740k and EBIT of EUR 10,418k (up from EUR 7,393k). The Netherlands segment delivered EUR 55,775k in external sales and an EBIT of EUR 10,750k (up from EUR 9,770k). The Americas/USA showed weaker operational performance in the table provided (e.g., an Americas segment with lower sales and a negative/weak EBIT in some subsegments), signalling mixed regional dynamics.

Investments, cash & financials

Group investments (excluding financial assets) were EUR 20,895k in 2024 (down from EUR 27,388k in 2023). Financial earnings were EUR 191k (2023: EUR 237k) while financial expenses were EUR 3,628k (2023: EUR 3,519k). Group liabilities decreased to EUR 150,684k (2023: EUR 162,711k) and Group net assets rose to EUR 280,289k.

R&D and strategic moves

Research and development spending rose to EUR 14,599k (2023: EUR 13,652k). In 2024 Uzin Utz acquired a 25.1% stake in FP Floor Protector GmbH for EUR 1,750k (goodwill recognized ~EUR 1,725k), intended to strengthen technology for parquet flooring.

Impairment/testing and outlook items

The Group performed impairment testing (value‑in‑use) for goodwill and CGUs (using pre‑tax discount rates reported in the September 30, 2024 testing range). Management notes continued planning uncertainty under current macro conditions; any material triggering events would prompt updates to impairment tests.

Other notable points

R&D capitalization policy is conservative (most development costs expensed). Contract liabilities (advance payments) were immaterial at EUR 113k at year‑end. The consolidated financial statements were prepared under IFRS and approved by management on March 13, 2025 (Supervisory Board approval March 27, 2025).